Department of Gynaecology and Obstetrics and the Department of Pathology, Copenhagen University Hospital Amager and Hvidovre, Hvidovre, and the Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark ; and the Cancer Prevention Group, School of Cancer & Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London, Guy's Cancer Centre, Great Maze Pond, London, United Kingdom .
Obstet Gynecol. 2021 Sep 1;138(3):389-397. doi: 10.1097/AOG.0000000000004522.
To compare the real-life screening outcomes after cytology was replaced by human papillomavirus (HPV) testing for women aged 60-64 years.
Using the Danish national pathology register, we compared screening outcomes during two consecutive calendar periods, one where women were screened with cytology and one where most women were screened with HPV testing. Our primary outcomes were the proportions of women with positive test results, high-grade cervical intraepithelial neoplasia (CIN 2 or worse), and cervical cancer.
Women screened during the HPV testing period were more likely to have a positive screening test result than were women screened during the cytology period (relative proportion 2.80, 95% CI 2.65-2.96). The detection of CIN 2 or worse was also increased (relative proportion 1.54, 95% CI 1.31-1.80), whereas there was no increase in screen-detected cervical cancer diagnoses (relative proportion 1.27, 95% CI 0.76-2.12). Within the first 4 years after a negative screening test result, including 168,477 woman-years at risk after a negative screen result in the HPV period and 451,421 woman-years after a negative screen result in the cytology period, the risk of a cervical cancer diagnosis was approximately 4 per 100,000 woman-years and was similar for both screening tests (relative risk 0.99, 95% CI 0.41-2.35).
Human papillomavirus testing led to more positive screening test results and diagnoses of high-grade CIN lesions. Few women were diagnosed with cervical cancer after a negative screening test result.
比较细胞学检查被人乳头瘤病毒(HPV)检测替代后,60-64 岁女性的实际筛查结果。
利用丹麦全国病理登记处的数据,我们比较了两个连续日历期间的筛查结果,一个期间女性接受细胞学筛查,另一个期间大多数女性接受 HPV 检测筛查。我们的主要结局是阳性检测结果、高级别宫颈上皮内瘤变(CIN2 或更高级别)和宫颈癌的女性比例。
接受 HPV 检测筛查的女性比接受细胞学筛查的女性更有可能出现阳性筛查检测结果(相对比例 2.80,95%CI2.65-2.96)。CIN2 或更高级别病变的检出率也有所增加(相对比例 1.54,95%CI1.31-1.80),而筛查诊断的宫颈癌病例并无增加(相对比例 1.27,95%CI0.76-2.12)。在首次阴性筛查检测结果后的前 4 年内,包括 HPV 检测时期阴性筛查结果后有 168477 人年风险和细胞学检测时期阴性筛查结果后有 451421 人年风险,宫颈癌诊断的风险约为每 100000 人年 4 例,两种筛查检测方法的风险相似(相对风险 0.99,95%CI0.41-2.35)。
HPV 检测导致更多的阳性筛查检测结果和高级别 CIN 病变的诊断。少数女性在阴性筛查检测结果后被诊断为宫颈癌。